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ABSTRACT  
In this study, we quantified the ability of opioids present in biological samples to 
activate the µ-opioid receptor and TLR4 using cell-based assays. Each assay was 
standardised, in the presence of plasma, using morphine, its µ receptor-active 
metabolite morphine-6 glucuronide (M6G) and its µ receptor-inactive, but TLR4-
active metabolite morphine-3 glucuronide (M3G). Specificity was verified using 
antagonists. Morphine- and M6G-spiked plasma samples exhibited µ receptor 
activation, which M3G-spiked plasma lacked. In contrast, M3G showed moderate but 
consistent activation of TLR-4. Plasma samples were collected at a number of time 
points from mice administered morphine (1 or 10 mg/kg every 12 h for 3 days) or 
saline. Morphine administration led to intermittent µ receptor activation, reversed by 
µ receptor antagonists, and to TRL4 activation at time points where M3G is 
measured in plasma. Interestingly, this protocol of morphine administration also led 
to TLR4-independent NF-κB activation, at time points where M3G was not detected, 
presumably via elevation of circulating cytokines including, but not limited to, TNFα. 
Circulating TNFα was increased after three days of morphine administration, and 
TNFα mRNA elevated in the spleen of morphine-treated mice. 
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1. INTRODUCTION 
Contemporary literature indicates that non-opioid receptors can be activated by 
opiates. The Toll-like receptor 4 (TLR4) has been recently examined in this context 
(Hutchinson et al., 2010b; Stevens et al., 2013). Opioids produce a slight but 
significant activation of TLR4 in a non-stereospecific fashion (i.e. the (+) isomer of 
morphine is active at TLR4 receptor but not at OR level) (Wang et al., 2012) while 
antagonising the effect of the natural ligand, LPS, in a non-competitive fashion 
(Stevens et al., 2013), presumably via binding to MD2 (Hutchinson et al., 2010b). 
The morphine metabolite, morphine-3-glucuronide (M3G), is able to activate TLR4 
signalling (Hutchinson et al., 2010b). Activation of TLR4 by opioids is proposed to 
mediate some of the undesirable effects of opioids, such as neuro-inflammation 
through central innate immune and endothelial cells (Grace et al., 2014; Wang et al., 
2012); contribution to the reinforcing/rewarding effects of opioids (Hutchinson et al., 
2012) and to morphine-induced suppression of colon peristalsis (Farzi et al., 2015); 
but also to modulate peripheral endogenous opioid-mediated analgesia in the 
context of inflammation (Sauer et al., 2014).  
In this study, we established new methods to quantify µ receptor and TLR-4 agonism 
in biological samples and have applied them to mouse plasma samples in order to 
demonstrate, for the first time, circulating receptor agonism in morphine-treated 
mice.  
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2. MATERIALS AND METHODS  
2.1 Materials  
DMEM, foetal bovine serum (FBS), trypsin-EDTA, penicillin/streptomycin and G418 
sulfate solutions were obtained from Invitrogen (Life Technologies, VIC, Australia). 
DBLTM morphine sulfate and naloxone were purchased from Hospira (Mulgrave, VIC, 
Australia). Morphine-6β-D-glucuronide (M6G), morphine-3β-D-glucuronide (M3G), 
morphine-D3, morphine-6β-D-glucuronide-D3 (M6G-D3), morphine-3β-D-glucuronide 
(M3G-D3) were purchased from Novachem (Collingwood, VIC, Australia).  
Methylnaltrexone (MNTX) was from Link Medical Products (Warriewood, NSW, 
Australia). Normocine™, HEK-Blue™ Selection, QUANTI-Blue™ and 
lipopolysaccharide from the photosynthetic bacterium Rhodobacter sphaeroides 
(LPS-RS) were obtained from Jomar Life Research (Scoresby, VIC, Australia). 3-
isobutyl-1-methylxanthine (IBMX) and forskolin (FSK) were supplied by Sapphire 
Bioscience (Redfern, NSW, Australia). AlamarBlue™ was purchased from Thermo 
Fisher Scientific (Life Technologies, VIC, Australia). The following reagents were 
purchased from Sigma-Aldrich (Castle Hill, NSW, and Australia): Amitriptyline, 
lipopolysaccharide (LPS) from E. Coli, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) and TweenTM 20. The mouse inflammation antibody array was 
purchased from Abcam (Melbourne, VIC, Australia). TNFα was from Lonza (Mount 
Waverley, VIC, Australia). AlphascreenTM cAMP assay kit for the evaluation of opioid 
receptor activation was obtained from PerkinElmer (MA, USA). 
2.2 Cell culture  
HEK-MOP cells (human embryonic kidney 293 cells stably transfected with µ-opioid 
receptor) were cultured in DMEM supplemented with 10% (v/v) FBS, 500 µg/mL 
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G418 sulfate, 100 U/mL penicillin and 100 µg/mL streptomycin. HEK-Blue™-hTLR4 
cells (human embryonic kidney 293 cells co-transfected with the human TLR4, MD-2 
and CD14 co-receptor genes) were cultured in DMEM supplemented with 10% (v/v) 
FBS, 50 U/mL penicillin, 50 µg/mL streptomycin, 100 µg/mL Normocin™ and 1X 
HEK-Blue™ Selection reagent to protect the stability of the transgenes. Both cell 
lines were incubated at 37°C in a 5% CO2 atmosphere. 
2.3 AlphaScreenTM cAMP Assay 
The µ receptor activation assay relies on measurements of cAMP by cells 
overexpressing the µ receptor and was performed according to the manufacturer’s 
instructions. Cyclic AMP was measured in 96-well plates with suspension cells in a 
total volume of 25 µL. Five µL of HEK-MOP cells in suspension (~25,000 cells), 
acceptor beads (at a final concentration of 15  µg/mL), and stim buffer (1x HBSS, 
1%BSA, 0.5 mM IBMX, 5 mM HEPES) mixture were added into each well previously 
filled with drugs or/and biological samples (5 µL in total volume) and incubated in the 
dark at room temperature for 30 min. Streptavidin donor beads and biotin cAMP in 
15 µL lysis buffer (0.1% BSA, 0.3% Tween-20, 5 mM HEPES) were then added, and 
the plates were incubated and shaken in the dark at room temperature overnight 
before reading in the Perkin EnVision-Alpha Reader 2101 (PerkinElmer, MA, USA).  
2.4 HEK-Blue™-hTLR4 assay (TLR4 signaling assay) 
The determination of TLR4 activation employs cells engineered to express hTLR4 
and MD-2/CD14 co-receptor genes, together with a secreted embryonic alkaline 
phosphatase (SEAP) reporter gene under NF-κB and AP-1 control. TLR4 activation 
results in NF-κB-dependent production of SEAP detected using a colorimetric 
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substrate placed in the cell culture medium. These HEK-Blue™-hTLR4 cells were 
seeded in a 96-well plate (10,000 cells/well). After 48 h incubation, the medium was 
replaced with serum-free medium. The cells were then treated with drugs and/or 
biological samples, and incubated for 12 h at 37°C in 5% CO2. A second-step 
QUANTI-Blue™ assay reagent was introduced to measure the level of secreted 
embryonic alkaline phosphatase (SEAP). QUANTI-Blue™ substrate was pre-
warmed at 37°C, then distributed in 180 µL aliquots per well to 96-well plates. 20 µL 
supernatant of treated cell culture media was then added and incubated for 4 h at 
37°C in 5% CO2. The plates were read at a wavelength of 655 nm with a 
spectrophotometer (Bio-Rad Laboratories Inc.). 
2.5 AlamarBlueTM Cell Viability Assay  
Cells were seeded in a 96-well plate (10,000 cells/well). After 48 h incubation, the 
medium was replaced with serum-free medium. The cells were then added with 
drugs, and incubated for 6 h at 37°C in 5% CO2. Control samples included untreated 
cells and background (culture medium without cells). A volume of 10 µL 
AlamarBlueTM (AB) reagent was then added yielding a final concentration of 10% 
AB in 100 µL / well assay volume. The plates were then incubated for an additional 6 
h and the absorbance was measured at a wavelength of 570 nm and 600 nm using a 
SPECTROstar Nano absorbance microplate reader. The calculation of the 
percentage of AB reduction (% AB reduction) was performed according to the 
manufacturer's protocol: 
%	Reduction	of	AB	Reagent =
600 × 570 − 570 × 600
 !570 × "600 −  !600 × "570
× 100 
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In the formula, Eoxi and Ered are molar extinction coefficient (E) of oxidized AB 
reagent at 570 and 600 nm, respectively (Eoxi = 80586 and Ered = 117216). A570 and 
A600 represent absorbance of test wells at 570 and 600 nm, respectively. C570 and 
C600 represent absorbance of negative control at 570 and 600 nm, respectively.  
2.6 Animals  
Reporting of the animal studies follows the ARRIVE guidelines (McGrath and Lilley, 
2015). Female Balb/c mice (6 weeks) from University of Queensland Biological 
Resources (The University of Queensland, QLD, Australia) were maintained on a 12 
h light/dark cycle in temperature- and humidity-controlled conditions with water and 
food supplied ad libitum. The University of Queensland Animal Ethics Committee 
approved all procedures involving mice (AEC Approval Number: 
PHARM/381/13/ANZCA), and they are conducted according to the Principles of 
Laboratory Animal Care (National Institutes of Health Publication 85-23, revised in 
1985).  
2.7 Morphine treatment and blood collection 
Mice were given an intra-peritoneal injection of 1 or 10 mg/kg of morphine or an 
equivalent volume of saline at 12 h intervals for three days. The 10 mg/kg dose was 
chosen because it is analgesic and leads to circulating concentrations of morphine in 
mice similar to the dose range we use in our in vitro experiments (Afsharimani et al., 
2014; Khabbazi et al., 2015), while the 1 mg/kg dose was selected to generate M3G 
concentrations that are lower and thus easier to compare to M3G concentrations in 
humans for TLR4 activation. To capture peak and trough concentrations of morphine, 
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the mice were euthanised for blood collection at 10 min and 12 h after the first (day 
1, D1) and last (day 3, D3) injection. 
2.8 Quantitative LC−MS/MS determination of morphine and morphine 
metabolites in biological samples 
Circulating concentrations of morphine, M6G and M3G were measured using an 
Agilent 6460 Triple Quadrupole system (Agilent Technologies, Santa Clara, CA, 
USA). The analytes were extracted from plasma samples (100 µL) using protein 
precipitation. Samples were extracted into 100% acetonitrile (Merck, Darmstadt, 
Germany), the acetonitrile dried down by nitrogen and the samples reconstituted in a 
mixture of 5% acetonitrile and water (Milli-Q system, Milford, USA) with 0.1% formic 
acid (Fisher Chemical, Geel, Belgium) prior to HPLC analysis. The analytes (M, 
M3G, M6G and the internal deuterated standards) were separated using reversed 
phase chromatography on a Poroshell 120 PFP (150 x 2.1 mm, 2.7 µm)-Agilent 
column (Agilent Technologies, Santa Clara, CA, USA) and eluted using 5% 
acetonitrile containing 0.1% formic acid as the mobile phase. The compounds were 
ionised using electrospray ionization, their m/z ratios were detected using tandem 
mass spectrometry running in the positive multiple reaction monitoring (MRM) mode, 
and their product ion transitions (M, 286.2-151.1 m/z; Morphine-D3, 289.2-155.1 m/z; 
M3G & M6G, 462.2-286.1 m/z; M3G-D3 & M6G-D3, 465.2-289.1 m/z) monitored to 
provide unequivocal quantitative data. Results were analyzed using a Mass Hunter 
Workstation software (Agilent Technologies, Santa Clara, CA, USA).  
2.9 Mouse inflammation antibody array  
The mouse inflammation antibody array was purchased from Abcam (Melbourne, 
VIC, Australia). The assay was carried out following the manufacturer’s protocol. 
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Three membranes were incubated separately in blocking buffer for 30 min at room 
temperature before overnight incubation at 4oC with an equal volume of combined 
serum collected from 3 individual mice undergoing the same treatment (D3 12 h, 
saline, morphine 1 mg/kg or morphine 10 mg/kg). The membranes were incubated in 
1X Biotin-Conjugated Anti-Cytokine antibodies (1 mL/membrane) at 4oC overnight. 
The following 2 h incubation step (at room temperature) for signal detection was 
carried out with 1X HPR-Conjugated Streptavidin (2 mL/membrane).  Between each 
incubation, a 2 steps washing was performed to reduce background interference. 
The array assay was performed twice with samples collected from two separated 
experiments. Chemiluminescence was detected using the ChemiDoc™ Touch 
Imaging System (Bio-Rad Laboratories Inc.). Optical density was analyzed using 
Image J software.  
2.10 Quantitative RT-PCR 
The expression of TNFα transcripts was quantified by real-time reverse transcriptase 
polymerase chain reaction (Real time RT-PCR). Total RNA was isolated from mouse 
tissue and purified using a Pure link™ RNA Mini Kit (Life Technologies, VIC, 
Australia). Purified RNA concentration was determined by 260 nm absorbance in a 
nano-drop spectrophotometer (Thermo Fisher Scientific, VIC, Australia). RNA was 
reverse transcribed to complementary DNA using a High-Capacity cDNA reverse 
transcription kit (Life Technologies, VIC, Australia) and cDNA quantified using using 
TaqMan™ Fast Universal PCR Master Mix (Life Technologies, VIC, Australia) with 
AmpliTaq Gold™ DNA Polymerase and TaqMan™ Gene Expression Assay for 
human TNFα (Hs01113624-g1) in a StepOnePlus 7500 real time PCR system 
(Applied Biosystems, Carlsbad, CA, USA). The amount of target gene was 
normalized to 18S ribosomal RNA (18S rRNA) control gene and quantification was 
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performed using the comparative critical threshold (Ct) method (Schamittgen and 
Livak 2008). 
2.11 ELISA quantification of TNFα 
The mouse TNF single analyte ELISA kit was obtained from QIAGEN (Melbourne, 
VIC, Australia). The concentrations of TNFα in serum collected from saline or 
morphine-treated mice were determined according to the manufacturer's instructions. 
Mouse serum (50 µl/well) was incubated with assay buffer in 8-well ELISArray strips 
for 2 h, with detection antibody for 1 h and with avidin-horseradish peroxidase for 30 
min. At least 3 washing steps were performed between each incubation. A substrate 
solution was added to each well for 15 min. The color development was stopped by 
addition of the stop solution and the absorbance at 450 nm was read in a 
spectrophotometer (Bio-Rad Laboratories Inc.). All incubation and washing steps 
were performed at room temperature. A standard curve was generated in a log-log 
graph for quantification. Protein amount of TNFα in experimental samples was 
determined based on the best straight-line curve fit through the points on the 
standard curve.  
2.12 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism software (v. 7.00). A P-
value of < 0.05 was considered significant. Data are presented as mean ± SEM of at 
least three replicates, independent experiments or individual mice as detailed in 
figure legends. To test three or more groups defined by one factor, data were 
analysed using One Way ANOVA with post hoc Dunnett's multiple comparison test. 
To compare individual groups of interest, data were analysed using Student’s t test. 
  
11 
 
 
  
  
12 
 
3. RESULTS 
3.1 Quantification of µ receptor agonism in the presence of plasma. 
In order to measure circulating µ receptor activity (resulting from the combination of 
exogenously administered and endogenously produced active factors), we have 
optimised the conditions to quantify µ receptor activation. The µ receptor activation 
determination is achieved via AlphascreenTM measurement of cAMP produced by µ 
receptor-overexpressing human embryonic kidney 293 cells (HEK-MOP cells). 
Cellular production of cAMP is measured by reference to a cAMP standard curve 
(Figure 1A). Forskolin (fsk)-induced cAMP production (Figure 1B) is decreased by 
Gi-coupled µ receptor; therefore, in this assay, decreased cAMP production reflects 
µ receptor activation. We have confirmed that morphine and its active metabolite 
M6G activate µ receptor (thus inhibiting fsk-induced cAMP production) while M3G 
does not reduce cAMP production (Figure 1C). Furthermore, naloxone and 
methylnaltrexone (MNTX) dose-dependently reverse the effect of morphine (Figure 
1D). Serum interfered with the assay and caused artefactually high readings of 
cAMP concentration (data not shown). We determined that plasma could be used up 
to 0.5 µl (a concentration of 5% of the assay volume) without significant interference 
with AMP measurement, and would permit the detection of µ receptor activation by 
morphine (Figure 2A). Plasma spiked with morphine or M6G concentrations as low 
as 1 nM caused significant inhibition of fsk-induced cAMP production while plasma 
spiked with M3G up to 1 µM did not (Figure 2B). Lastly, naloxone and 
methylnaltrexone (MNTX) can be added to the assay to demonstrate µ receptor 
involvement in the detected activity (Figure 2C). 
3.2 Quantification of TLR4 receptor activation in the presence of plasma. 
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We measured TLR4 activation by LPS in HEK-Blue™ cells and determined that 
plasma was a better option than serum to apply this assay to mouse samples (Figure 
3A). TLR4 activation by LPS was reversed by the TLR4 antagonist LPS-RS (Figure 
3B) and by amitriptyline (Hutchinson et al., 2010a) at concentrations that did not 
induce loss of HEK-Blue™ cell viability (Figure 3C). The µ receptor-inactive 
morphine metabolite M3G is a weak but consistent activator of the TLR4 in the 
absence or presence of 5% plasma, while in our experimental conditions, morphine 
(with a modest but significant increase at only one of the concentrations tested) and 
M6G are not (Figure 4A). TLR4 involvement in the observed activation was verified 
using the specific TLR4 antagonist, LPS-RS (Figure 4B) as well as by amitriptyline 
(Figure 4C) at concentrations that did not result in loss of HEK-Blue™ cell viability 
(Figure 4D and 4E, up to 30 µM amitriptyline).  
3.3 Plasma from morphine-treated mice activates µ receptor  
The ability of plasma from morphine treated mice to activate µ receptor was detected 
at some, but not all time points and treatment doses. When present, the activation 
was comparable to that obtained with 1-100 nM morphine, which, when accounting 
for the 5% dilution of plasma in the assay, would correspond to high nM, low µM 
morphine concentrations in the plasma (if all activity was due to non-metabolised 
morphine).  Mu opioid receptor agonism was present in the plasma of morphine-
treated mice 10 min after the first injection, but not 12 h after injection, indicating that 
the mice are subjected to intermittent µ receptor activation arising from the protocol 
that we employed (Figure 5A). Accordingly, no morphine was measured in plasma at 
the D1 12 h time point (Figure 5B). Activation of µ receptor was seen 10 min after the 
final injection even in mice treated with 1 mg/kg morphine (Figure 5A). Interestingly, 
at the D3 12h time point, there was significant µ receptor activation present (Figure 
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5A) but no morphine was detected (Figure 5B). We hypothesised that the activity 
was due to a µ receptor-active metabolite; accordingly, µ receptor activation detected 
in all samples was reversed by 1 µM naloxone (Figure 6 A-D). As expected (Milne et 
al., 1996), M6G was not detected in any of the samples by LC-MS/MS (Data not 
shown).  
3.4 Plasma from morphine-treated mice activates TLR4  
Our results show, for the first time, TLR4 activation by plasma of morphine-treated 
mice (Figure 7A). This was statistically significant at 10 min and 12 h after the last 
injection for both the 1 and 10 mg/kg doses. Mean ± SD concentrations of M3G of 
4.9 ± 1.6 and 7.7 ± 2.2 µM were found in the plasma of 1 mg/kg morphine-treated 
mice 10 min after the first and last injection, respectively. Mean concentrations of 
M3G of 39.3 ± 11.8 and 68.9 ± 9.1 µM were found in the plasma of 10 mg/kg 
morphine-treated mice 10 min after the first and last injections, respectively. No M3G 
was detected 12 h after injections, indicating that exposure to this metabolite is also 
intermittent when using 12 h separated IP injections of morphine. Most intriguingly, 
the activity at the D3 12 h time point did not correlate with the presence / 
concentration of M3G in plasma (Figure 7B). The TLR4 assay relies on NF-κB 
activation in TLR4 over-expressing cells. To assess whether the activity detected at 
D3 12 h might be due to NF-ΚB activation independent of TLR4, we repeated the 
assay in the presence of the TLR4 antagonist LPS-RS (Figure 8). The antagonist 
reversed the activity of D1 10 min plasma, (compatible with M3G present in the 
sample activating TLR4), but only partially reversed the activity of D3 10 min plasma 
and did not alter the activity of the D3 12 h plasma. These results indicate that the 
mice subjected to the protocol of morphine administration that we employed: (i) 
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exhibit circulating TLR4 activation correlating with the presence of M3G; and (ii) 
accumulate, within 3 days, circulating TLR4-independent, NF-κB activating factor(s). 
3.5 HEK-Blue™ cells can increase secreted embryonic alkaline phosphatase 
(SEAP) production in response to TLR4-independent signals. 
To test whether SEAP production in HEK-Blue™ cells can be triggered in a TLR4-
independent fashion, we compared the activation induced by LPS (Figure 9A) and 
TNFα (Figure 9B) and showed that TNFα at concentrations above 1 ng/mL indeed 
elicited SEAP production. While the LPS-induced activation of SEAP production was 
reversed by the specific TLR4 antagonist LPS-RS (Figure 9C), the activation induced 
by TNFα was not reversed by LPS-RS (Figure 9D). This suggests that mice treated 
with intermittent IP injections of morphine for 3 days have increased circulating 
concentrations of TNFα and/or other cytokines and factors resulting in NF-κB-
dependent activation of SEAP in the HEK-Blue™ cells. We verified whether this 
might be the case for TNFα by comparing the levels of TNFα and its soluble 
receptors sTNFR I and II in the serum of saline and morphine-treated mice (Figure 
10A and 10B). We measured a slight but consistent increase in the circulating TNFα 
concentration in mice administered morphine compared to saline controls. In 
contrast, there was no change in the concentrations of circulating TNFR I or II. We 
confirmed the increase in circulating TNFα in morphine-treated mice using ELISA 
quantification (Figure 10C). The concentration of TNFα measured in serum was 
below the threshold required for in vitro activation of TLR4 in the reporter cell line 
(Figure 9B), indicating that TNFα is not the only NF-κB activating factor increased in 
the circulation of morphine-treated mice. In an attempt to identify the origin of the 
increased TNFα found in the circulation, organs were collected from mice treated 
with saline or 10 mg/kg morphine and the tissue expression of TNFα mRNA was 
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determined. The mRNA was induced by a factor ~3 in the spleen of morphine-treated 
mice (Figure 10D), in favor of an effect of morphine intermittent administration on 
TNFα production by immune cells. These results suggest that other NF-κB-activating 
factors may be increased in the morphine-treated mice, which together with TNFα 
may explain the LPS-RS-unaltered increased production of SEAP in HEK-Blue™ at 
time points where M3G is not measured in the circulation.  
3.6 Plasma from morphine-treated mice inhibits LPS-induced TLR4 activation  
Opioids are reported to inhibit LPS-induced TLR4 activation (Stevens et al., 2013). 
We tested whether M3G and morphine altered the TLR4 activation induced by 1 
ng/mL LPS across a wide range of concentrations, covering the range of 
concentrations of M3G and morphine found in the plasma of morphine treated mice 
(Figure 11A). Both M3G and morphine significantly decreased the TLR4 signal, with 
a maximum effect of ~50% inhibition. To examine whether this would be relevant in 
vivo, we tested the effect of plasma from morphine or saline-treated mice added at 
0.5 µl (or 5% (v/v) of the reaction volume), on LPS-induced TLR4 activation (Figure 
11B). At time points where M3G and morphine were detected in plasma, there was a 
statistically significant inhibition of TLR4 signal with a maximum inhibition of ~38% 
observed with plasma from 10 mg/kg morphine-treated mice collected 10 minutes 
after the final injection.  
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4. DISCUSSION 
This study has demonstrated for the first time that the administration of morphine to 
mice results in circulating M3G concentrations and TLR4 activation, compatible with 
a clinically relevant effect on TLR4-expressing cells. Of note, and as previously 
reported in in vitro experiments (Hutchinson et al., 2010b) the activation of TLR4 by 
M3G is modest compared to that elicited by natural ligand LPS. Future experiments 
will have to examine whether TLR4 activation by M3G has functional consequences 
in vivo. In addition to modest activation of the TLR4, opioids have been shown to 
significantly decrease LPS-induced activation of TLR4, by a mechanism suggested 
to be non-competitive antagonism (Stevens et al., 2013). We confirm that morphine, 
and reveal that M3G, both alter LPS-induced TLR4 over a range of concentrations 
observed in the circulation of morphine-treated mice. Interestingly, our study 
discloses that plasma of morphine-treated mice can prevent LPS-induced TLR4 
activation only at time points when morphine and M3G are present. This suggests 
that the net effect of morphine (and possibly other opioids) administration on the 
immune system may vary greatly depending on the presence of TLR4 activating 
factors such as endotoxin or danger-associated molecular patterns (DAMPs) and 
that opioid modulation of innate immunity and inflammation via TLR4 may have 
relevance in pathological contexts.  
Our results also show that the administration of morphine to mice every 12 h results 
in discontinuous circulating µ receptor agonism. There is a paucity of information in 
the preclinical or clinical literature regarding the effect of intermittent vs. continuous 
morphine administration on immune parameters. Intermittent morphine (every 12 h 
for 4 days) is documented to be a stressor, activating the hypothalamo-pituitary-
adrenal (HPA) axis, and promoting a stress response (Houshyar et al., 2003) in rats. 
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It has been proposed that natural killer (NK) cell suppression in heroin 
(diacetylmorphine) addicts may result from multiple daily withdrawals, while 
neuroendocrine and immune functions normalise upon µ receptor exposure to the 
long-acting agonist methadone (Kreek, 1996). On the other hand, in rodents, 
morphine-induced NK cell suppression is subject to tolerance whether morphine 
administration is discontinuous (daily SC injections) (Shavit et al., 1986), or 
continuous (via mini-pumps) (West et al., 1998).  
Our results serendipitously show that intermittent morphine administration results in 
the production, within 3 days, of circulating NF-κB-activating factor(s) that act 
independently of TLR4, including (but most likely not limited to) TNFα. Increased 
TNFα has been documented in association with dependence and withdrawal. In rats 
rendered morphine-dependent by escalating IP injections of morphine every 12 h (10 
to 40 mg/kg) for 5 days, precipitated withdrawal by naloxone injection (4 mg/kg) 
resulted, within 1 h, in increased TNFα expression in the brain periaqueductal grey 
matter (Hao et al., 2011). C3HeB/FeJ female mice subjected to morphine withdrawal 
(implanted with a 75 morphine pellet for 48 h which was then surgically removed for 
24 h) were shown to react to LPS administration by an increased (more than two-
fold) TNFα concentration in serum collected 6 h after LPS injection, compared to 
placebo pellet-inserted mice (Rahim et al., 2004). Similar results were obtained with 
an experimental design where tolerance was induced over 96 h and withdrawal 
assessed 24 h following removal of the pellets (Feng et al., 2005). In this latter study, 
TNFα serum concentration and splenic mRNA expression were tested in morphine-
withdrawn mice challenged with saline instead of LPS, and there was no detectable 
increase compared to placebo pellet-inserted mice, indicating that morphine 
withdrawal per se is insufficient to induce TNFα using this experimental protocol. 
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Taken together with our current results, this raises an interesting consideration of the 
choice of pharmacokinetic characteristics and mode of administration of opioid 
analgesia to patients. 
One pathological context where our findings may have translational relevance is 
tumor growth and metastasis. Both µ receptors and TLR4 can be activated by 
opioids or their metabolites, are expressed on cancer cells and tumour-associated 
cells, and control signalling pathways important in cancer metastasis. Cancer cells 
and immune cells, such as macrophages in the tumour microenvironment, are able 
to respond to TLR4 ligands (Ikebe et al., 2009; Liao et al., 2012). The actions of 
opioids at TLR4 may contribute to their net effect, both promoting and preventing 
tumour growth and metastasis. TLR4 signalling in cancer cells can increase their 
ability to invade (Ikebe et al., 2009; Liao et al., 2012); TLR agonists are, however, 
also powerful immunostimulants, now becoming part of the anticancer therapeutic 
arsenal (Adams, 2009). Endogenous TLR4 agonists such as danger-associated 
molecular patterns (DAMPs), released by cancer cells upon chemotherapeutic 
treatment, activate dendritic cells and promote an anti-tumour T-cell response (Fang 
et al., 2014). Recently, perioperative treatment with a TLR4 agonist in rats and mice 
was documented to reduce cancer metastasis (Matzner et al., 2015), seemingly via 
an increased immune response towards the cancer cells. Preclinical research on the 
influence of opioids on cancer is abundant and discrepant, with morphine or other 
opioid agonists documented to promote, prevent or have no effect on tumour growth 
or metastasis. To the factors likely to explain the conflicting results, which we have 
previously reviewed (Afsharimani et al., 2015), our current study now adds TLR4 as 
a confounding factor. Firstly, mice differ greatly in their ability to respond to TRL4 
agonists (Poltorak et al., 1998; Sultzer, 1968; Tsukamoto et al., 2013). If the action of 
  
20 
 
opioids on TLR4 contributes to the response of the host to tumours, the mouse strain 
employed must be taken into consideration. Similarly cancer cells derived from mice 
with deficient TLR4 signalling (e.g. 4T1 breast cancer cells originate from BALB/c 
mice) may respond differently to opioids or their metabolites. Another level of 
variability between mouse strains is their ability to biotransform opioids into 
metabolites with TLR4 activation ability such as M3G, which in our experiments is a 
more potent activator of the TLR4 than morphine (Figure 4A), and is found at high 
concentrations in morphine-treated mice (Figure 7B). Mouse species differences in 
UDP-glucuronosyl transferase (UGT) activities are documented (Shiratani et al., 
2008). Lastly, we have previously identified the continuity of administration as a 
factor likely generating discrepancies in the outcomes of preclinical studies exploring 
the influence of morphine on tumour growth and metastasis (Afsharimani et al., 
2015). This is now reinforced by the finding that TNFα is induced in mice subjected 
to discontinuous µ receptor activation, and could potentially be evaluated in mouse 
tumour model(s) comparing continuous osmotic mini-pump administration to IP 
injections separated by 12 h.  
Our preclinical study shows that intermittent morphine administration results in 
increased TNFα production and suggests a novel non-opioid-mediated role for 
morphine administration, including weak activation of the TLR4 by M3G, but effective 
antagonism by both M3G and morphine in the presence of the pro-inflammatory 
TLR4 ligand, LPS. The assays we have developed can be applied to clinical samples 
to further elucidate the effect of morphine administration on the immune system. 
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FIGURE LEGENDS 
Figure 1. Determination of µ-opioid receptor activation by measurement of cAMP 
production. A) Standard curve of cAMP signal-concentration relationship. B) 
Concentration-dependent increase in cellular cAMP levels upon forskolin stimulation. 
C) Production cAMP in response to 10nM and 1µM of morphine, M6G or M3G. All 
samples were adjusted to contain the same volume of solvent, i.e. saline for 
morphine, water:methanol (80:20) for M6G, methanol with 0.05% sodium hydroxide 
(w/v) for M3G. Data are shown as mean ± SEM, n=3 replicates. D) Concentration-
dependent reversal of the effect of morphine on FSK-induced cAMP production by µ 
receptor antagonists. Indicated concentrations of naloxone and methylnaltrexone 
were included in the reaction system which contained 1 µM of morphine, and 
receptor activation was determined by the Alphascreen™ cAMP assay. *, p<0.05, **, 
p<0.01, ***, p<0.001, ****, p<0.0001, morphine ± naloxone or methylnaltrexone vs 
FSK, One way ANOVA with Dunnett’s multiple comparison. Data are shown as mean 
± SEM, n=3 replicates. 
Figure 2. Optimisation of the µ-opioid receptor activation assay with plasma. A) 
Different volumes of plasma were tested in the reaction system. µ receptor activation 
by 10 nM morphine was determined by the AlphascreenTM cAMP assay. Values are 
expressed as the % of cAMP produced in the presence of forskolin alone. *, p<0.05, 
****, p<0.0001, forskolin + 0.5 µl plasma versus forskolin + 0.5 µl plasma and 
morphine, unpaired Student’s t test. Mean ± SEM is shown, n=3 replicates. B) 
Screening of 0.5µL plasma spiked with morphine, M6G or M3G at indicated 
concentrations. µ receptor activation was determined by the AlphascreenTM cAMP 
assay. *, p<0.05, ****, p<0.0001, plasma spiked with morphine or M6G vs 0.5 µL 
plasma alone (+FSK), One way ANOVA with Dunnett’s multiple comparisons. Mean 
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± SEM is shown, n=6. C) Modulation of cAMP production in the presence of 
antagonists. Indicated concentrations of naloxone and methylnaltrexone were mixed 
with the reaction system which contained 0.5 µL of plasma and 1 µM morphine, and 
receptor activation was determined by the AlphascreenTM cAMP assay. *, p<0.05, **, 
p<0.01, ***, p<0.001, morphine, morphine + naloxone or morphine + 
methylnaltrexone vs plasma alone + FSK, One way ANOVA with Dunnet’s multiple 
comparisons. Data are shown as mean ± SEM, n=3 replicates. 
Figure 3. Optimization of the determination of TLR4 activation. A) HEK-Blue™ 
hTLR4 cells were treated with LPS at increasing concentrations (0-1000 ng/mL) in 
the absence or presence of 5% (v/v) plasma or serum for 12 h. 20 µL cell 
supernatant was added to 180 µL QUANTI-Blue™ substrate and incubated for an 
additional 4 h. The response ratio (absorbance at 655 nm for LPS-treated cells / 
absorbance at 655 nm for control cells) was calculated and plotted as a function of 
LPS concentration. Data are shown as mean ± SEM, n=3 replicates. B, C) Reversal 
of LPS-induced SEAP production by TLR4 inhibitors. Indicated concentrations of 
LPS-RS or amitriptyline were added to cells stimulated with 1 ng/mL LPS, and 
receptor activation was determined by the QUANTI-Blue™ assay. ***, p<0.001, ****, 
p<0.0001, LPS + LPS-RS or amitriptyline vs LPS alone, One way ANOVA with 
Dunnet’s multiple comparisons. Data are shown as mean ± SEM, n=3 replicates. D, 
E) Determination of cell viability in the presence of LPS-RS and TLR4 inhibitors. 
HEK-Blue™ hTLR4 cells were exposed to 1 ng/ml LPS and various concentrations 
of LPS-RS (D) or amitriptyline (E) for 6 h. Cells were then added with AlamarBlue 
Reagent, incubated for a further 6 h, and the absorbance was measured at 570 nm / 
600 nm. Cell viability is shown as the percentage of AlamarBlue™ reagent reduction. 
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****, p<0.0001, amitriptyline and LPS-RS vs LPS alone, one way ANOVA with 
Dunnett’s multiple comparison test. Data are shown as mean ± SEM, n=3 replicates. 
Figure 4. M3G activates TLR4. A) HEK-Blue™ hTLR4 cells were incubated in cell 
culture media and stimulated with indicated concentrations of M3G, morphine or 
M6G. After 12 h incubation, the levels of SEAP were measured with two-step 
QUANTI-Blue™. *, p<0.05, **, p<0.01, ****, p<0.0001, morphine or M3G treatment 
vs media control, One way ANOVA with Dunnet’s multiple comparisons. Data are 
shown as mean ± SEM, n=6 replicates. B, C) Reversal of M3G-induced SEAP 
production by TLR4 inhibitors. Indicated concentrations of LPS-RS and amitriptyline 
were added to cells stimulated with M3G, and receptor activation was determined by 
the QUANTI-Blue™ assay. *, p<0.05, ***, p<0.001, ****, p<0.0001, M3G + LPS-RS 
or amitriptyline vs M3G alone, One way ANOVA with Dunnet’s multiple comparisons. 
Data are shown as mean ± SEM, n=6 replicates (LPS-RS) and n=3 replicates 
(amitriptyline). D, E) Determination of cell viability in the presence of M3G and TLR4 
inhibitors. HEK-Blue™ hTLR4 cells were exposed to 10 µM M3G and various 
concentrations of LPS-RS (D) or amitriptyline (E) for 6 h. Cells were then added with 
AlamarBlue Reagent, incubated for a further 6 h, and the absorbance was measured 
at 570 nm / 600 nm. Cell viability is shown as the percentage of AlamarBlue™ 
reagent reduction. *, p<0.05, **, p<0.01, ***, p<0.001, ****, p<0.0001, LPS-RS or 
amitriptyline vs M3G alone, One way ANOVA with Dunnet’s multiple comparisons. 
Data are shown as mean ± SEM, n=3 replicates. 
Figure 5. A) Plasma of morphine-treated mice activates µ receptor. Mice were 
treated with morphine (1 or 10 mg/kg) every 12 h for up to 3 days and blood samples 
collected at indicated times. µ receptor activation was determined by the 
AlphascreenTM cAMP assay using 0.5 µL plasma into 100 µL reaction system. White 
  
27 
 
bars show a standard curve of morphine concentrations, *, p<0.05, **, p<0.01, ***, 
p<0.001, ****, p<0.0001, morphine vs no morphine, One way ANOVA with Dunnet’s 
multiple comparisons.  Mouse plasma samples were tested at 5% (v/v): *, p<0.05, **, 
p<0.01, unpaired Student’s t test. Results are shown as mean ± SEM, n = 3 
individual mice. B) Morphine concentration in mouse plasma. Morphine was 
quantified using LC−MS/MS. Data are shown as mean ± SEM, n=3 individual mice 
and expressed as µM morphine. 
Figure 6. Effect of µ receptor antagonist naloxone on receptor activation by plasma 
of morphine-treated mice. Mouse plasma samples (0.5 µL) as well as 1 µM naloxone 
were added to the AlphascreenTM cAMP reaction system simultaneously, and cellular 
cAMP production was then measured. *, p<0.05, **, p<0.01, ***, p<0.001, unpaired 
Student’s t test. Mean ± SEM is shown, n=3 individual mouse samples. 
Figure 7. A) Plasma of morphine treated mice activates TLR4. Mice were treated 
with morphine (1 or 10 mg/kg) every 12 h for up to 3 days and blood samples 
collected at indicated times. HEK-Blue™ hTLR4 cells were stimulated with 5% (v/v) 
mouse plasma. After 12 h incubation, the levels of NF-kB-induced SEAP were 
determined using two-step QUANTI-Blue™. White bars show a standard curve of 
M3G concentrations, *, p<0.05, **, p<0.01, ****, p<0.0001, M3G vs no M3G, One 
way ANOVA with Dunnet’s multiple comparisons.  Mouse plasma samples were 
tested at 5% (v/v): *, p<0.05, **, p<0.01, unpaired Student’s t test. Results are shown 
as mean ± SEM, n=3 individual mice. B) M3G concentration in mouse plasma. M3G 
was quantified using LC−MS/MS. Data are shown as mean ± SEM, n=3 individual 
mice and expressed as µM M3G. 
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Figure 8. Effect TLR4 antagonist on receptor activation by plasma from morphine-
treated mice.  HEK-Blue™ hTLR4 cells were co-treated with 1 µg/mL LPS-RS and 
5% morphine-treated mouse plasma. After 12 h incubation, the levels of NF-kB-
induced SEAP were determined with two-step QUANTI-Blue™ *, p<0.05, **, p<0.01, 
unpaired Student’s t-test. Mean ± SEM is shown, n=3 individual mouse samples. 
Figure 9. TNFα stimulates HEK-Blue™ hTLR4 cells SEAP production. A, B) HEK-
Blue™ hTLR4 cells were treated with LPS (A) or TNFα (B) at indicated 
concentrations for 12 h. Cell supernatant (20 µL) was added to 180 µL QUANTI-
Blue™ substrate and incubated for 4 h. The response ratio (absorbance at 655 nm 
for LPS-treated cells / absorbance at 655 nm for control cells) was calculated and 
plotted as a function of cytokine concentration. C, D) Indicated concentrations of 
LPS-RS were added to cells stimulated with LPS (C) or TNFα (D), and SEAP 
production was determined by the QUANTI-Blue™ assay. ****, p<0.0001 One way 
ANOVA with Dunnet’s multiple comparisons (LPS 1ng/ml) and unpaired Student’s t 
test (LPS 100 ng/ml). Mean ± SEM is shown, n=3 replicates.  
Figure 10. Morphine treatment increases circulating TNFα. A) Serum from 3 
morphine- (1 mg/kg, 10 mg/kg) or saline-treated mice were combined and added to 
mouse inflammation antibody array membranes. Chemiluminescence was detected 
using the ChemiDoc™ Touch Imaging System. B) Data were normalized to positive 
control according to the manufacturer’s instructions, and presented as % of the 
signal intensities of saline control. Mean ± SEM is shown, n=4 determinations each 
performed with serum from 3 individual mice mixed in equal parts. C) ELISA 
quantification of TNFα in mouse serum samples. *, p<0.05, **, p<0.01, morphine- 
versus saline-treated mice, unpaired Student’s t test. Mean ± SEM is shown, n=6 
individual mice per group.  D) Organs were collected from saline or morphine (10 
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mg/kg)-treated mice at Day 3 10 min and the levels of TNFα mRNA determined by 
qRT-PCR. Results are shown as mean ± SEM, n=6 individual mice per group. ****, 
p<0.0001, unpaired Student’s t-test. 
Figure 11. Effect of morphine or M3G on LPS-induced TLR4 activity. A) HEK-Blue™ 
hTLR4 cells were treated with indicated concentrations of morphine or M3G in 
combination with 1 ng/mL LPS. After 12h incubation, the activity of SEAP was 
determined by two-step QUANTI-Blue™ assay. **, p<0.01, ***, p<0.001, ****, 
p<0.0001. LPS + morphine or M3G vs LPS alone, One way ANOVA with Dunnet’s 
multiple comparisons. Results are shown as mean ± SEM, n=3 replicates. B) Mice 
were treated with morphine (1 or 10 mg/kg) every 12 h for up to 3 days and blood 
samples collected at indicated times. HEK-Blue™ hTLR4 cells were treated with 1 
ng/mL LPS and 5% (v/v) mouse plasma. After 12 h incubation, the levels of NF-kB-
induced SEAP were determined using two-step QUANTI-Blue™.*, p<0.05, **, 
p<0.01, unpaired Student’s t test. Results are shown as mean ± SEM, n= 6 individual 
mice. 
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STUDY HIGHLIGHTS 
• Both µ-opioid receptor and TLR4 can be activated by opioids or their metabolites 
• Cell based assays can be used to quantify receptor agonism in biological samples  
• Morphine administration results in circulating MOR and TLR4 agonism  
• IP injections of morphine to mice every 12 h lead to intermittent MOR activation 
• This mode of morphine administration results in TLR4-independent NF-κB 
activation 
 
 
 
